Treatment of Zollinger-Ellison Syndrome With Prevacid

Charles Mel Wilcox, MD

Status and phase: Completed; Phase 4

Conditions: Zollinger-Ellison Syndrome; Multiple Endocrine Neoplasia

Treatments: Drug: Lansoprazole (Prevacid)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00204373

F030107005

Details and patient eligibility

About

The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.

Full description

The aim of this protocol is to study the medical management of acid hypersecretory states including Zollinger-Ellison using Prevacid. The immediate objective is to heal peptic ulcers and eliminate symptoms and in the long term to prevent relapse of symptoms, lesions and complications. Other objectives include observation of the efficacy in controlling gastric acid production and of the safety of high dose, long-term use of Prevacid.

Enrollment: 72 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with Zollinger-Ellison syndrome

Exclusion criteria

• Pregnant or lactating females

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

72 participants in 1 patient group

single group

Experimental group

Description:

This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.

Treatment:

Drug: Lansoprazole (Prevacid)